Breast implant illness (BII) — a constellation of systemic symptoms that some patients with breast implants attribute to their implants — has driven a global explant trend, with patients seeking removal of devices they associate with health concerns. Korean clinics, traditionally focused on breast augmentation, have developed explant capability to serve patients seeking implant removal. This update covers the 2026 landscape.
What breast implant illness refers to
- Self-reported symptom cluster attributed to breast implants.
- Common symptoms: fatigue, joint pain, brain fog, hair loss, anxiety.
- Less common: skin issues, autoimmune symptoms, headaches.
- Variable in presentation.
- Not formally recognized as distinct medical diagnosis.
- Many patients report symptom resolution after explant.
The medical and regulatory context
Status
- BII not formally recognized in major diagnostic systems.
- FDA acknowledges symptoms patients report.
- FDA mandates BII risk disclosure on consent forms (2021).
- Korean MFDS similar disclosure requirements.
- Active research into mechanism and prevalence.
What\'s known
- Some patients report symptom resolution after explant.
- Mechanism unclear — autoimmune? Bacterial biofilm? Anxiety-mediated?
- Both saline and silicone implants reported.
- Both textured and smooth surface reported.
- Other implant complications well-established (capsular contracture, BIA-ALCL).
What patients should know
- Symptoms are real even if mechanism unclear.
- Other causes of symptoms should be ruled out.
- Explant is reasonable option for patients attributing symptoms to implants.
- Outcomes variable — many but not all patients improve.
- Comprehensive medical workup recommended before explant.
Korean clinical response
Specialized explant clinics
- Some Korean plastic surgery clinics now offer explant-focused services.
- En-bloc capsulectomy capability.
- Reconstruction options if patient desires.
- Comprehensive consultation regarding outcomes.
Evolution from augmentation focus
- Korean breast surgery historically augmentation-dominant.
- Increasing demand for explant has driven specialty development.
- Surgeons trained in both augmentation and explant.
- Honest discussions about realistic explant outcomes.
Explant procedure types
Simple implant removal
- Implant removed without capsule.
- Capsule remains in body.
- Faster procedure, less recovery.
- Some patients prefer if capsule healthy.
- Less invasive but doesn\'t address capsule.
Total capsulectomy
- Implant and entire capsule removed.
- Standard for BII concerns.
- Entire fibrous capsule excised.
- More extensive procedure.
- Longer recovery.
En-bloc capsulectomy
- Implant and intact capsule removed as single specimen.
- Capsule never opened during surgery.
- Considered gold standard for BII concerns.
- More technically demanding.
- Longer surgery time.
- Higher cost.
Explant with breast lift (mastopexy)
- Combined approach for sagging after explant.
- Removes excess skin.
- Reshapes natural tissue.
- More extensive scar.
- Two-stage approach if extensive.
Explant with fat grafting
- Patient\'s own fat used to restore some volume.
- Avoids alloplastic implants.
- Multiple sessions may be needed.
- Modest volume restoration possible.
What patients can expect from explant
Aesthetic outcome
- Loss of implant volume — breasts smaller after explant.
- Skin and tissue changes after extended implant period.
- Some sagging often present.
- Asymmetry possible.
- Reconstruction options for those wanting volume restoration.
Symptom outcomes
- Variable — many but not all patients report improvement.
- Improvement may be gradual over months.
- Some symptoms resolve fully; others partially.
- Realistic expectations important.
Recovery from explant
- Outpatient or one-night admission.
- Drains for 3–7 days.
- Compression bra for 4–6 weeks.
- Initial recovery 1–2 weeks.
- Final shape settles 3–6 months.
- Scar maturation 12 months.
Pricing in Korean clinics 2026
- Simple implant removal: ₩3,000,000–₩6,000,000.
- Total capsulectomy: ₩5,000,000–₩9,000,000.
- En-bloc capsulectomy: ₩7,000,000–₩12,000,000.
- Combined with mastopexy: ₩9,000,000–₩15,000,000.
- Combined with fat grafting: ₩9,000,000–₩18,000,000.
Pre-operative evaluation
- Comprehensive medical history.
- Symptom documentation.
- Imaging (mammogram, ultrasound, possibly MRI).
- Implant identification and rupture screening.
- Other-cause workup for symptoms.
- Discussion of expected outcomes.
- Reconstruction or no-reconstruction decision.
For patients considering explant
Factors favoring explant
- Persistent symptoms attributed to implants.
- Stable preference for removal.
- Other causes of symptoms ruled out.
- Acceptance of aesthetic changes.
- Realistic expectations.
Considerations before explant
- Workup for other causes of symptoms.
- Discuss with primary care or appropriate specialist.
- Mental health context affecting symptom interpretation.
- Acceptance that symptoms may not fully resolve.
- Long-term aesthetic implications.
For Korean clinics serving explant patients
Best practices
- Comprehensive consultation about realistic outcomes.
- Avoid overpromising symptom resolution.
- Coordinated medical workup.
- En-bloc capability when appropriate.
- Honest discussion of aesthetic implications.
- Reconstruction discussion if relevant.
The Korean perspective
- Cultural shift from augmentation-dominant to inclusive of explant.
- Medical-tourism patients seeking specialized explant care.
- Clinics adapting to changing patient demand.
- Respect for patient autonomy in body decisions.
- Ongoing research and clinical observation.
What\'s evolving in 2026
- Increased awareness of BII and patient choice.
- Improved en-bloc capsulectomy techniques.
- Better fat grafting for post-explant restoration.
- More clinic transparency about explant outcomes.
- Continued research into BII mechanism.
- Possible regulatory changes regarding implant disclosure.
The honest framing
Breast implant illness is a real concern for patients regardless of formal diagnostic recognition — symptoms patients experience are genuine, even when the connection to implants remains scientifically uncertain. Korean clinics increasingly offer specialized explant services, with en-bloc capsulectomy as the gold-standard approach for BII concerns. The patients who navigate this well work up other causes, set realistic expectations about both symptom and aesthetic outcomes, and choose surgeons with explicit explant experience rather than augmentation-focused practitioners. The patients who pursue explant expecting complete symptom resolution and unchanged aesthetics are sometimes disappointed; the patients who accept the aesthetic trade-offs and partial symptom outcomes typically report satisfaction with the choice.